PMID- 22488211
OWN - NLM
STAT- MEDLINE
DCOM- 20121011
LR  - 20211021
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 35
IP  - 6
DP  - 2012 Jun
TI  - Inhaled low-dose iloprost for pulmonary hypertension: a prospective, multicenter, 
      open-label study.
PG  - 365-70
LID - 10.1002/clc.21987 [doi]
AB  - BACKGROUND: Inhaled iloprost (average >30 microg/d) has been considered an effective 
      treatment for severe pulmonary hypertension (PH). Further evidence also showed 
      that low-dose iloprost given intravenously was equally effective as high-dose 
      iloprost in the therapy of systemic sclerosis. HYPOTHESIS: Patients with 
      pulmonary hypertension will benefit from inhalation of low-dose iloprost. 
      METHODS: Sixty-two patients with PH were enrolled and initiated with 
      neubulizedlow-dose iloprost (2.5 microg per inhalation, 6x daily) for 24 weeks in 13 
      medical centers in China. Efficacy endpoints included changes in 6-minute walk 
      distance (6MWD), World Health Organization functional class (WHO-FC), and 
      hemodynamic parameters. RESULTS: Fourteen patients (22.6%) prematurely 
      discontinued the study: 8 due to clinical worsening (6 in WHO-FCIII-IV at 
      baseline), 4 because of protocol change, and 2 patients lost during follow-up. In 
      the remaining 48 patients, 6MWD was increased from 356 +/- 98 meters to 414 +/- 99 
      meters (P < 0.001) and WHO-FC improved significantly (P = 0.006) after 24-week 
      inhalation therapy. Cardiac output, cardiac index, and mixed venous oxygen 
      saturation improved significantly compared with baseline (n = 34, P < 0.05). Most 
      of the hemodynamic parameters improved significantly in patients in WHO-FC II (P 
      < 0.05) but not in patients in WHO-FCIII-IV. CONCLUSIONS: Low-dose iloprost 
      inhalation significantly improved exercise capacity and functional status in 
      patients with PH. It was well tolerated. The improvement of hemodynamics was 
      confirmed in patients with WHO-FCI-II but not in patients with WHO-FCIII-IV, 
      suggesting the importance of early treatment in patients with advanced disease 
      stages.
CI  - (c) 2012 Wiley Periodicals, Inc.
FAU - Sun, Yun-Juan
AU  - Sun YJ
AD  - Center for Diagnosis and Management of Pulmonary Vascular Diseases, Department of 
      Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, 
      National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Xiong, Chang-Ming
AU  - Xiong CM
FAU - Shan, Guang-Liang
AU  - Shan GL
FAU - Gu, Qing
AU  - Gu Q
FAU - Zeng, Wei-Jie
AU  - Zeng WJ
FAU - Lu, Xian-Ling
AU  - Lu XL
FAU - Zhu, Feng
AU  - Zhu F
FAU - Liu, Zhi-Hong
AU  - Liu ZH
FAU - Ni, Xin-Hai
AU  - Ni XH
FAU - He, Jian-Guo
AU  - He JG
CN  - Iloprost Therapy on Pulmonary Hypertension Study Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20120409
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - JED5K35YGL (Iloprost)
SB  - IM
MH  - Administration, Inhalation
MH  - Adult
MH  - China
MH  - Exercise Tolerance/drug effects
MH  - Female
MH  - Health Status Indicators
MH  - Heart Rate
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Hypertension, Pulmonary/*drug therapy/pathology
MH  - Iloprost/administration & dosage/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption
MH  - Prospective Studies
MH  - Statistics as Topic
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC6652663
FIR - Zhou, Da-Xin
IR  - Zhou DX
FIR - Lv, An-Kang
IR  - Lv AK
FIR - Yu, Zai- Xin
IR  - Yu Z
FIR - Cao, Hua
IR  - Cao H
FIR - Huang, Yi-Gao
IR  - Huang YG
FIR - Shen, Jie-Yan
IR  - Shen JY
FIR - Bao, Chun-De
IR  - Bao CD
FIR - Yang, Yuan-Hua
IR  - Yang YH
FIR - Wu, Bing-Xiang
IR  - Wu BX
FIR - Li, Meng-Tao
IR  - Li MT
FIR - Yang, Rong
IR  - Yang R
FIR - Yang, Zhen-Wen
IR  - Yang ZW
FIR - Cheng, Zhao-Zhong
IR  - Cheng ZZ
EDAT- 2012/04/11 06:00
MHDA- 2012/10/12 06:00
PMCR- 2012/04/09
CRDT- 2012/04/11 06:00
PHST- 2011/11/27 00:00 [received]
PHST- 2012/02/27 00:00 [revised]
PHST- 2012/04/11 06:00 [entrez]
PHST- 2012/04/11 06:00 [pubmed]
PHST- 2012/10/12 06:00 [medline]
PHST- 2012/04/09 00:00 [pmc-release]
AID - CLC21987 [pii]
AID - 10.1002/clc.21987 [doi]
PST - ppublish
SO  - Clin Cardiol. 2012 Jun;35(6):365-70. doi: 10.1002/clc.21987. Epub 2012 Apr 9.